12:00 AM
 | 
Nov 05, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Regorafenib regulatory update

Bayer and partner Onyx Pharmaceuticals Inc. (NASDAQ:ONXX, South San Francisco, Calif.) said FDA accepted for review and granted Priority Review to an NDA for regorafenib to treat metastatic and/or unresectable gastrointestinal stromal tumors (GIST) in patients whose disease...

Read the full 176 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >